The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants

ConclusionsEarly recurrence within 1  year from transplant was the most significant risk factor. Treatment efficacy and adverse events and tolerability of sorafenib were comparable with those in the setting of advanced HCC without transplant.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research